Annual report
4886.TEDINET S100OHVN
Period2021-04-01 → 2022-03-31
Filed2022-06-28
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 37
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥56.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Operating income | ¥4.8bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥4.9bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥6.2bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥4.3bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥4.3bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥83.3bn | at 2022-03-31 | Cons. | Assets |
| Total liabilities | ¥34.4bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥48.9bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥44.5bn | at 2021-03-31 | Cons. | Net assets |
| Cash and deposits | ¥12.1bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥17.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.5bn | at 2021-03-31 | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥2.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥6.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥3.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥151.22 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥1,734.8 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 58.7% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 8.8% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| Employees | 777 | at 2022-03-31 | Cons. | Number of employees |
| Revenue | ¥1.4bn | 2021-04-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Operating income | ¥717m | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥717m | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Profit before tax | ¥717m | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥682m | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Total assets | ¥41.3bn | at 2022-03-31 | Standalone | Assets |
| Total liabilities | ¥606m | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥40.7bn | at 2022-03-31 | Standalone | Net assets |
| Cash and deposits | ¥820m | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥23.79 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥15 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,443.94 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 98.5% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 1.7% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 30,563,199 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Employees | 74 | at 2022-03-31 | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 24
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2021-04-01 → 2022-03-31 | ¥5m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2022-03-31 | 48 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2022-03-31 | ¥5.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2022-03-31 | ¥5.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥73m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2022-03-31 | ¥3.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2022-03-31 | ¥360m |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥136m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥73m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥73m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥37.3bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥653m |
| Pharmaceutical Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥2.5bn |
| Pharmaceutical Businessreportable segment | employees | at 2022-03-31 | 649 pure |
| Pharmaceutical Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥50.8bn |
| Pharmaceutical Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥50.8bn |
| Pharmaceutical Businessreportable segment | segment assets | at 2022-03-31 | ¥42.9bn |
| Pharmaceutical Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥5.1bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥2.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥56.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥56.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥73m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥46.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥5.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,041
| Item | Context | Value | Unit |
|---|---|---|---|
| Basic earnings loss per share (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 23.79 | |
| Diluted earnings per share (5-year summary) | CurrentYearDuration_NonConsolidatedMember | － | |
| Equity to asset ratio (5-year summary) | CurrentYearInstant_NonConsolidatedMember | 0.985 | |
| Rate of return on equity (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 0.0168 | |
| Price earnings ratio (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 53.10 | |
| Payout ratio (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 0.336 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 74 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | － | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | － | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E35791-000PharmaceuticalBusinessReportableSegmentsMember | 649 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E35791-000PharmaceuticalBusinessReportableSegmentsMember | 75 | |
| Number of employees | CurrentYearInstant_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 48 | |
| Average number of temporary workers | CurrentYearInstant_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 10 | |
| Number of employees | CurrentYearInstant_CorporateSharedMember | 80 | |
| Average number of temporary workers | CurrentYearInstant_CorporateSharedMember | 16 | |
| Number of employees | CurrentYearInstant | 777 | |
| Average number of temporary workers | CurrentYearInstant | 101 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 74 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 46 | |
| Average age months information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 8 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 21 | |
| Average length of service months information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 2 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 9817337 | JPY |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 74 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 74 | |
| Research and development expenses research and development activities | CurrentYearDuration | 3598000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 2277000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 30563199 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 30563199 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 30563199 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 30563199 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 23 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 26 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 64 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 109 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 12 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 7629 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 7863 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 87239 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 5518 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 78492 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 37066 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 43 | |
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 97062 | |
| Number of shares held number of units total | CurrentYearInstant_OrdinaryShareMember | 305420 | |
| Number of shares held shares less than one unit | CurrentYearInstant_OrdinaryShareMember | 21199 | |
| Percentage of shareholdings national and local governments | CurrentYearInstant_OrdinaryShareMember | － |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |